WO2009025117A1 - Cdca1ペプチド及びこれを含む薬剤 - Google Patents
Cdca1ペプチド及びこれを含む薬剤 Download PDFInfo
- Publication number
- WO2009025117A1 WO2009025117A1 PCT/JP2008/060837 JP2008060837W WO2009025117A1 WO 2009025117 A1 WO2009025117 A1 WO 2009025117A1 JP 2008060837 W JP2008060837 W JP 2008060837W WO 2009025117 A1 WO2009025117 A1 WO 2009025117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- same
- pharmaceutical agent
- seq
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 101150033450 NUF2 gene Proteins 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0815578A BRPI0815578B8 (pt) | 2007-08-20 | 2008-06-13 | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina |
CA2696701A CA2696701C (en) | 2007-08-20 | 2008-06-13 | Cdca1 peptide and pharmaceutical agent comprising the same |
EP08777198.6A EP2186889B1 (en) | 2007-08-20 | 2008-06-13 | Cdca1 peptide and pharmaceutical agent comprising the same |
ES08777198.6T ES2537323T3 (es) | 2007-08-20 | 2008-06-13 | Péptido CDCA1 y agente farmacéutico que lo comprende |
PL08777198T PL2186889T3 (pl) | 2007-08-20 | 2008-06-13 | Peptyd CDCA1 i środek farmaceutyczny go zawierający |
RU2010110564/10A RU2486195C2 (ru) | 2007-08-20 | 2008-06-13 | Пептид cdca1 и включающее его фармацевтическое средство |
US12/673,434 US8598125B2 (en) | 2007-08-20 | 2008-06-13 | CDCA1 peptide and pharmaceutical agent comprising the same |
MX2010002001A MX2010002001A (es) | 2007-08-20 | 2008-06-13 | Peptido cdca1 y agente farmaceutico que comprende elmismo. |
DK08777198.6T DK2186889T3 (en) | 2007-08-20 | 2008-06-13 | CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS |
CN2008801123961A CN101835892B (zh) | 2007-08-20 | 2008-06-13 | Cdca1肽和包含cdca1肽的药剂 |
AU2008290061A AU2008290061B2 (en) | 2007-08-20 | 2008-06-13 | CDCA1 peptide and pharmaceutical agent comprising the same |
JP2009528970A JP5493076B2 (ja) | 2007-08-20 | 2008-06-13 | Cdca1ペプチド及びこれを含む薬剤 |
IL203898A IL203898A (en) | 2007-08-20 | 2010-02-11 | Cdca1 protein, a pharmaceutical that contains it and uses it to treat cancer |
HK10107732.6A HK1141312A1 (en) | 2007-08-20 | 2010-08-13 | Cdca1 peptide and pharmaceutical agent comprising the same cdca1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007214000 | 2007-08-20 | ||
JP2007-214000 | 2007-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009025117A1 true WO2009025117A1 (ja) | 2009-02-26 |
Family
ID=40378024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/060837 WO2009025117A1 (ja) | 2007-08-20 | 2008-06-13 | Cdca1ペプチド及びこれを含む薬剤 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8598125B2 (ja) |
EP (1) | EP2186889B1 (ja) |
JP (1) | JP5493076B2 (ja) |
KR (1) | KR101610353B1 (ja) |
CN (1) | CN101835892B (ja) |
AU (1) | AU2008290061B2 (ja) |
BR (1) | BRPI0815578B8 (ja) |
CA (1) | CA2696701C (ja) |
DK (1) | DK2186889T3 (ja) |
ES (1) | ES2537323T3 (ja) |
HK (1) | HK1141312A1 (ja) |
IL (1) | IL203898A (ja) |
MX (1) | MX2010002001A (ja) |
PL (1) | PL2186889T3 (ja) |
PT (1) | PT2186889E (ja) |
RU (2) | RU2486195C2 (ja) |
SG (1) | SG183698A1 (ja) |
TW (1) | TWI523660B (ja) |
WO (1) | WO2009025117A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009153992A1 (en) * | 2008-06-19 | 2009-12-23 | Oncotherapy Science, Inc. | Cdca1 epitope peptides and vaccines containing the same |
US7943295B2 (en) | 2005-07-29 | 2011-05-17 | Oncotherapy Science, Inc. | Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex |
WO2013133405A1 (ja) | 2012-03-09 | 2013-09-12 | オンコセラピー・サイエンス株式会社 | ペプチドを含む医薬組成物 |
US8569244B2 (en) | 2007-08-20 | 2013-10-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
US8617562B2 (en) | 2009-02-18 | 2013-12-31 | Oncotherapy Science, Inc. | FOXM1 peptides and immunogenic compositions containing them |
WO2014010229A1 (en) * | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Cdca1 epitope peptides for th1 cells and vaccines containing the same |
WO2016021508A1 (ja) * | 2014-08-04 | 2016-02-11 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
JP2019135494A (ja) * | 2010-05-14 | 2019-08-15 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
WO2020027239A1 (ja) | 2018-08-02 | 2020-02-06 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11834718B2 (en) | 2013-11-25 | 2023-12-05 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status |
US11939637B2 (en) | 2014-12-19 | 2024-03-26 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0815578B8 (pt) | 2007-08-20 | 2021-05-25 | Oncotherapy Science Inc | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
IL254129B2 (en) | 2015-03-27 | 2023-10-01 | Immatics Biotechnologies Gmbh | New peptides and a combination of peptides for use in immunotherapy against various tumors |
DK3573600T3 (da) | 2017-01-25 | 2022-05-09 | Ose Immunotherapeutics | Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH06317688A (ja) | 1993-02-01 | 1994-11-15 | General Electric Co <Ge> | 複合核燃料容器およびそれの製造方法 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1999008521A1 (en) | 1997-08-14 | 1999-02-25 | Department Of The Army, U.S. Government | Treatment or prophylaxis of retinal pathology and spinal cord injury |
JPH11510507A (ja) | 1995-08-03 | 1999-09-14 | リュークスウニベルジテート トゥ ライデン | 細胞由来の抗原提示小胞 |
JP2000512161A (ja) | 1997-07-16 | 2000-09-19 | アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル | 「エキソソーム」と呼ばれる細胞内小胞、調製及び免疫刺激におけるこれらの使用 |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2002094981A2 (en) * | 2001-05-16 | 2002-11-28 | Technion Research And Development Foundation Ltd. | Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses |
WO2005089735A2 (en) * | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Compositions and methods for treating lung cancer |
JP2006500949A (ja) * | 2002-09-30 | 2006-01-12 | オンコセラピー・サイエンス株式会社 | 非小細胞肺癌の診断のための方法 |
WO2007013480A2 (en) * | 2005-07-29 | 2007-02-01 | Oncotherapy Science, Inc. | Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex |
WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | T細胞レセプター及び該レセプターをコードする核酸 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002516572A (ja) | 1997-05-23 | 2002-06-04 | バイオジェン,インコーポレイテッド | 組織の再生の調節 |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6858204B2 (en) * | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
BR0012069A (pt) | 1999-06-30 | 2002-08-27 | Corixa Corp | Composições e métodos para a terapia e diagnóstico de câncer pulmonar |
US20020172952A1 (en) * | 1999-06-30 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030211510A1 (en) * | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
AU7721500A (en) * | 1999-09-29 | 2001-04-30 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
AU2002218770A1 (en) | 2000-07-11 | 2002-01-21 | Corixa Corporaton | Compositions and methods for the therapy and diagnosis of lung cancer |
US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
AU2002327945A1 (en) * | 2001-09-17 | 2003-04-01 | Eirx Therapeutics Limited | Human delta-n p73 molecules and uses thereof |
WO2003105891A2 (en) | 2002-06-12 | 2003-12-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of hec1 antagonists in the treatment of proliferative disorders and cancer |
CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
JP2006500946A (ja) | 2002-09-30 | 2006-01-12 | オンコセラピー・サイエンス株式会社 | 精巣精上皮腫の診断方法 |
WO2004080148A2 (en) | 2002-10-02 | 2004-09-23 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
CA2507924A1 (en) | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
EP1615658A1 (en) * | 2003-03-25 | 2006-01-18 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
WO2005029067A2 (en) * | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
EP2295601A1 (en) * | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
EP2298895A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
EP2311986B1 (en) * | 2005-07-27 | 2015-04-15 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
US7776341B2 (en) * | 2006-08-10 | 2010-08-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
BRPI0815578B8 (pt) | 2007-08-20 | 2021-05-25 | Oncotherapy Science Inc | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina |
TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1抗原決定位胜肽及含此胜肽的疫苗 |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
-
2008
- 2008-06-13 BR BRPI0815578A patent/BRPI0815578B8/pt active IP Right Grant
- 2008-06-13 DK DK08777198.6T patent/DK2186889T3/en active
- 2008-06-13 KR KR1020107005388A patent/KR101610353B1/ko active IP Right Grant
- 2008-06-13 AU AU2008290061A patent/AU2008290061B2/en active Active
- 2008-06-13 JP JP2009528970A patent/JP5493076B2/ja active Active
- 2008-06-13 RU RU2010110564/10A patent/RU2486195C2/ru active
- 2008-06-13 ES ES08777198.6T patent/ES2537323T3/es active Active
- 2008-06-13 CN CN2008801123961A patent/CN101835892B/zh active Active
- 2008-06-13 SG SG2012058327A patent/SG183698A1/en unknown
- 2008-06-13 WO PCT/JP2008/060837 patent/WO2009025117A1/ja active Application Filing
- 2008-06-13 MX MX2010002001A patent/MX2010002001A/es active IP Right Grant
- 2008-06-13 US US12/673,434 patent/US8598125B2/en active Active
- 2008-06-13 CA CA2696701A patent/CA2696701C/en active Active
- 2008-06-13 PT PT87771986T patent/PT2186889E/pt unknown
- 2008-06-13 EP EP08777198.6A patent/EP2186889B1/en active Active
- 2008-06-13 PL PL08777198T patent/PL2186889T3/pl unknown
- 2008-06-16 TW TW097122386A patent/TWI523660B/zh active
-
2010
- 2010-02-11 IL IL203898A patent/IL203898A/en active IP Right Grant
- 2010-08-13 HK HK10107732.6A patent/HK1141312A1/xx unknown
-
2013
- 2013-03-20 RU RU2013112616/10A patent/RU2013112616A/ru not_active Application Discontinuation
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5569825A (en) | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
JPH06317688A (ja) | 1993-02-01 | 1994-11-15 | General Electric Co <Ge> | 複合核燃料容器およびそれの製造方法 |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH11510507A (ja) | 1995-08-03 | 1999-09-14 | リュークスウニベルジテート トゥ ライデン | 細胞由来の抗原提示小胞 |
JP2000512161A (ja) | 1997-07-16 | 2000-09-19 | アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル | 「エキソソーム」と呼ばれる細胞内小胞、調製及び免疫刺激におけるこれらの使用 |
WO1999008521A1 (en) | 1997-08-14 | 1999-02-25 | Department Of The Army, U.S. Government | Treatment or prophylaxis of retinal pathology and spinal cord injury |
WO2002094981A2 (en) * | 2001-05-16 | 2002-11-28 | Technion Research And Development Foundation Ltd. | Method of identifying peptides capable of binding to mhc molecules, peptides identified thereby and their uses |
JP2006500949A (ja) * | 2002-09-30 | 2006-01-12 | オンコセラピー・サイエンス株式会社 | 非小細胞肺癌の診断のための方法 |
WO2005089735A2 (en) * | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Compositions and methods for treating lung cancer |
WO2007013480A2 (en) * | 2005-07-29 | 2007-02-01 | Oncotherapy Science, Inc. | Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex |
WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | T細胞レセプター及び該レセプターをコードする核酸 |
Non-Patent Citations (61)
Title |
---|
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, article "Molecular Cloning" |
"Molecular Cloning: A laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR |
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual" |
BENMOHAMED L ET AL., HUM. IMMUNOL., vol. 61, no. 8, 2000, pages 764 - 79 |
BETTER; HORWITZ, METHODS ENZYMOL, vol. 178, 1989, pages 476 - 96 |
BIRD; WALKER, TRENDS BIOTECH, vol. 9, 1991, pages 132 - 7 |
BOCZKOWSKI D ET AL., J EXP. MED., vol. 184, 1996, pages 465 - 72 |
BUTTERFIELD LH ET AL., J. IMMUNOL., vol. 161, 1998, pages 5607 - 13 |
CO ET AL., J IMMUNOL, vol. 152, 1994, pages 2968 - 76 |
DALBADIE-MCFARLAND G, PROC NATL ACAD SCI USA, vol. 79, 1982, pages 6409 - 13 |
DELUCA J.G.; MOREE, B.; HICKEY, J.M.; KILMARTIN, J.V.; SALMON, E.D.: "hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells", J. CELL BIOL., vol. 159, 2002, pages 549 - 555, XP002335933, DOI: doi:10.1083/jcb.200208159 |
DELUCA JG ET AL., CURR. BIOL., vol. 13, 2003, pages 2103 - 9 |
DELUCA JG, J. CELL BIOL., vol. 159, 2002, pages 549 - 55 |
DELUCA JQ ET AL., J. CELL BIOL., vol. 159, 2002, pages 549 - 55 |
DELUCA, J.G.; DONG, Y.; HERGERT, P; STRAUSS, J.; HICKEY, J.M.; SALMON, E.D.; MCEWEN, B.F.: "Hecl and Nuf2 Are Core Components of the Kinetochore Outer Plate Essential for Organizing Microtubule Attachment Sites.", MOL. BIOL. CELL, vol. 16, 2005, pages 519 - 531 |
DELUCA, J.G.; HOWELL, B.J.; CANMAN, J.C.; HICKEY, J.M.; FANG, G.; SALMON, E.D. ET AL.: "Nuf2 and Heel Are Required for Retention of the Checkpoint Proteins Madl and Mad2 to Kinetochores.", CURRENT BIOLOGY, vol. 13, 2003, pages 2103 - 2109 |
DERES K. ET AL., NATURE, vol. 342, 1989, pages 561 - 4 |
FALKENBURG JH ET AL., BLOOD, vol. 94, 1999, pages 1201 - 8 |
G. KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
HAYAMA S ET AL., CANCER RES, vol. 66, 2006, pages 10339 - 48 |
HAYAMA, S.; DAIGO, Y.; KATO, T.; ISHIKAWA, N.; YAMABUKI, T.; MIYAMOTO, M.; ITO, T.; TSUCHIYA, E.; KONDO, S.; NAKAMURA, Y: "Activation of CDCAI-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis.", CANCER RES., vol. 66, 2006, pages 10339 - 10348, XP002410940, DOI: doi:10.1158/0008-5472.CAN-06-2137 |
HIPP JD ET AL., IN VIVO, vol. 14, 2000, pages 571 - 85 |
HOOGENBOOM; WINTER, J MOL BIOL, vol. 227, 1992, pages 381 - 8 |
HUSTON ET AL., PROC NATL ACAD SCI USA, vol. 85, 1998, pages 5879 - 83 |
J. IMMUNOL., vol. 148, 1992, pages 1438 |
JOHNSON AG., CLIN. MICROBIOL. REV., vol. 7, 1994, pages 277 - 89 |
KAWAKAMI ET AL., J. IMMUNOL., vol. 142, 1989, pages 3452 - 3461 |
KOMORI H ET AL., CLIN. CANCER RES., vol. 12, 2006, pages 2689 - 97 |
KOMORI H, CLIN. CANCER RES., vol. 12, 2006, pages 2689 - 2697 |
KOMORI H, CLINICAL CANCER RESEARCH, vol. 12, 2006, pages 2689 - 2697 |
KONDO A, J. IMMUNOL., vol. 155, 1995, pages 4307 - 12 |
KUBO RT ET AL., J. IMMUNOL., vol. 152, 1994, pages 3913 - 24 |
KUGLER A, NAT MED, vol. 6, 2000, pages 332 - 6 |
LAMOYI, METHODS ENZYMOL, vol. 121, 1986, pages 652 - 63 |
LIU D ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 21415 - 24 |
LIU, D.; DING, D.; DU, J.; CAI, XIN.; HUANG, Y.; WARD, T.; SHAW, A.; YANG, Y.; HU, R.; JIN, C.: "Human NUF2 Interacts with Centromere-associated Protein E and Is Essential for a Stable Spindle Microtubule-Kinetochore Attachment", J.BIOL.CHEM., vol. 282, 2007, pages 21415 - 21424, XP002602449, DOI: doi:10.1074/JBC.M609026200 |
LIU, S.T.; RATTNER, J.B.; JABLONSKI, S.A.; YEN, T.J.: "Mapping the assembly pathways that specify formation of the trilaminar kinetochore plates in human cells.", J.CELLBIOL., vol. 175, 2006, pages 41 - 53 |
MAKITA M ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 2626 - 31 |
MARK DF ET AL., PROC NATL ACAD SCI USA, vol. 81, 1984, pages 5662 - 6 |
MIYOSHI H ET AL., J. VIROL., vol. 72, 1998, pages 8150 - 8157 |
MORGAN ET AL., J. IMMUNOL., vol. 171, 2003, pages 3288 |
NAKAHARA S ET AL., CANCER RES., vol. 63, 2003, pages 4112 - 8 |
NATURE, vol. 344, 1990, pages 873 |
PLUCKTHUN; SKERRA, METHODS EMZYMOL, vol. 178, 1989, pages 497 - 515 |
RAMMENSEE HQ ET AL., IMMUNOGENETICS, vol. 41, 1995, pages 178 - 228 |
REEVES ME ET AL., CANCER RES., vol. 56, 1996, pages 5672 - 7 |
ROSENBERG SA ET AL., NAT MED, vol. 4, 1998, pages 321 - 7 |
ROUSSEAUX ET AL., METHODS ENZYMOL, vol. 121, 1986, pages 663 - 9 |
See also references of EP2186889A4 |
SHATA MT ET AL., MOL. MED. TODAY, vol. 6, 2000, pages 66 - 71 |
SHEDLOCK DJ; WEINER DB. ET AL., J. LEUKOC. BIOL., vol. 68, 2000, pages 793 - 806 |
STOVER CK, NATURE, vol. 31, 1991, pages 456 - 60 |
SUDA T ET AL., CANCER SCI., 2007 |
SUDA T, CANCER SCI., vol. 98, 2007, pages 1803 - 8 |
TAHARA-HANAOKA S ET AL., EXP. HEMATOL., vol. 30, 2002, pages 11 - 17 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 6 |
WIGGE PA. ET AL.: "The Ndc80p complex from Saccharomyces cerevisiae contains conserved centromere components and has a function in chromosome segregation", J.CELL BIOL., vol. 152, no. 2, 2001, pages 349 - 360, XP002263372 * |
YOKOMINE K ET AL., CANCER SCI., vol. 98, 2007, pages 1930 - 5 |
YOSHITAKE Y ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 6437 - 48 |
ZOLLER MJ; SMITH M, NUCLEIC ACIDS RES, vol. 10, 1982, pages 6487 - 500 |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943295B2 (en) | 2005-07-29 | 2011-05-17 | Oncotherapy Science, Inc. | Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex |
US8569244B2 (en) | 2007-08-20 | 2013-10-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
US9073968B2 (en) | 2007-08-20 | 2015-07-07 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
US9415096B2 (en) | 2007-08-20 | 2016-08-16 | OncoTherapy Sciences, Inc. | FOXM1 peptide and medicinal agent comprising the same |
US9387238B2 (en) | 2008-06-19 | 2016-07-12 | Oncotherapy Science, Inc. | CDCA1 epitope peptides and vaccines containing the same |
WO2009153992A1 (en) * | 2008-06-19 | 2009-12-23 | Oncotherapy Science, Inc. | Cdca1 epitope peptides and vaccines containing the same |
US10711047B2 (en) | 2008-06-19 | 2020-07-14 | Oncotherapy Science, Inc. | CDCA1 epitope peptides and vaccines containing the same |
US8617562B2 (en) | 2009-02-18 | 2013-12-31 | Oncotherapy Science, Inc. | FOXM1 peptides and immunogenic compositions containing them |
JP7008049B2 (ja) | 2010-05-14 | 2022-02-10 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
JP2019135494A (ja) * | 2010-05-14 | 2019-08-15 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
WO2013133405A1 (ja) | 2012-03-09 | 2013-09-12 | オンコセラピー・サイエンス株式会社 | ペプチドを含む医薬組成物 |
US9687538B2 (en) | 2012-07-10 | 2017-06-27 | Oncotherapy Science, Inc. | CDCA1 epitope peptides for Th1 cells and vaccines containing the same |
WO2014010229A1 (en) * | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Cdca1 epitope peptides for th1 cells and vaccines containing the same |
US10206989B2 (en) | 2012-07-10 | 2019-02-19 | Oncotherapy Science, Inc. | CDCA1 epitope peptides for Th1 cells and vaccines containing the same |
US20150190490A1 (en) * | 2012-07-10 | 2015-07-09 | Oncotherapy Science, Inc. | Cdca1 epitope peptides for th1 cells and vaccines containing the same |
JP2015529629A (ja) * | 2012-07-10 | 2015-10-08 | オンコセラピー・サイエンス株式会社 | Th1細胞のCDCA1エピトープペプチドおよびこれを含有するワクチン |
US11834718B2 (en) | 2013-11-25 | 2023-12-05 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
US11452768B2 (en) | 2013-12-20 | 2022-09-27 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
JP7266318B2 (ja) | 2014-08-04 | 2023-04-28 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
US10676514B2 (en) | 2014-08-04 | 2020-06-09 | Oncotherapy Science, Inc. | CDCA1-derived peptide and vaccine containing same |
JP2020062031A (ja) * | 2014-08-04 | 2020-04-23 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
JP6999185B2 (ja) | 2014-08-04 | 2022-02-04 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
JP2022050382A (ja) * | 2014-08-04 | 2022-03-30 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
RU2699543C2 (ru) * | 2014-08-04 | 2019-09-06 | Онкотерапи Сайенс, Инк. | Пептид, полученный из cdca1, и содержащая его вакцина |
KR20170040315A (ko) | 2014-08-04 | 2017-04-12 | 온코세라피 사이언스 가부시키가이샤 | Cdca1-유래 펩티드 및 이를 포함하는 백신 |
WO2016021508A1 (ja) * | 2014-08-04 | 2016-02-11 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
EP4282883A2 (en) | 2014-08-04 | 2023-11-29 | OncoTherapy Science, Inc. | Cdca1-derived peptide and vaccine containing same |
JPWO2016021508A1 (ja) * | 2014-08-04 | 2017-05-18 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
US11939637B2 (en) | 2014-12-19 | 2024-03-26 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
KR20210040106A (ko) | 2018-08-02 | 2021-04-12 | 온코세라피 사이언스 가부시키가이샤 | Cdca1유래 펩타이드 및 이를 포함하는 백신 |
WO2020027239A1 (ja) | 2018-08-02 | 2020-02-06 | オンコセラピー・サイエンス株式会社 | Cdca1由来ペプチドおよびそれを含むワクチン |
Also Published As
Publication number | Publication date |
---|---|
EP2186889A1 (en) | 2010-05-19 |
US20110152199A1 (en) | 2011-06-23 |
PL2186889T3 (pl) | 2015-09-30 |
BRPI0815578A2 (pt) | 2015-02-18 |
DK2186889T3 (en) | 2015-06-08 |
SG183698A1 (en) | 2012-09-27 |
KR20100063060A (ko) | 2010-06-10 |
RU2013112616A (ru) | 2014-09-27 |
JP5493076B2 (ja) | 2014-05-14 |
BRPI0815578B8 (pt) | 2021-05-25 |
MX2010002001A (es) | 2010-03-11 |
IL203898A0 (en) | 2011-07-31 |
AU2008290061A1 (en) | 2009-02-26 |
KR101610353B1 (ko) | 2016-04-07 |
CA2696701A1 (en) | 2009-02-26 |
ES2537323T3 (es) | 2015-06-05 |
US8598125B2 (en) | 2013-12-03 |
EP2186889B1 (en) | 2015-04-01 |
HK1141312A1 (en) | 2010-11-05 |
CN101835892B (zh) | 2013-11-06 |
JPWO2009025117A1 (ja) | 2010-11-18 |
CA2696701C (en) | 2017-01-24 |
BRPI0815578B1 (pt) | 2020-04-07 |
AU2008290061B2 (en) | 2014-01-30 |
TWI523660B (zh) | 2016-03-01 |
IL203898A (en) | 2013-11-28 |
RU2010110564A (ru) | 2011-09-27 |
PT2186889E (pt) | 2015-06-17 |
CN101835892A (zh) | 2010-09-15 |
EP2186889A4 (en) | 2010-11-10 |
RU2486195C2 (ru) | 2013-06-27 |
TW200916114A (en) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009025117A1 (ja) | Cdca1ペプチド及びこれを含む薬剤 | |
WO2009025116A1 (ja) | Cdh3ペプチド及びこれを含む薬剤 | |
RS50966B (sr) | Agonisti pyy i njihova upotreba | |
MX2011011960A (es) | Peptidos penetradores de celulas. | |
WO2007056362A3 (en) | Glucagon analogs exhibiting physiological solubility and stability | |
WO2005030797A3 (en) | Melanocortin receptor agonists | |
WO2003083118A1 (fr) | Genes codant l'acetolactase synthase | |
EP2476697A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
WO2007048857A8 (es) | USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE | |
WO2009023300A3 (en) | Mutants of cholesterol-dependent cytolysins and uses thereof | |
WO2007097903A3 (en) | Hiv fusion inhibitor peptides with improved biological properties | |
WO2009025196A1 (ja) | Foxm1ペプチドおよびこれを含む薬剤 | |
EP2039367A4 (en) | PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES | |
WO2005068632A8 (ja) | HLA−A2402拘束性Ep−CAM特異的CTLが認識するエピトープ・ペプチド及びその用途 | |
WO2008105178A1 (ja) | リポソーム用生体成分抵抗性増強剤及びこれにより修飾されたリポソーム | |
EP2481748A3 (en) | Foxp3 peptide vaccine | |
WO2008113536A8 (en) | Neurotrophic peptides | |
EP1842911A4 (en) | HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS | |
WO2008084478A8 (en) | Anti-bacterial peptides and methods of treating diseases using same | |
WO2006090090A3 (fr) | Epitopes de vih et composition pharmaceutique les contenant | |
NZ589365A (en) | Peptidyl diacylglycerides | |
DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
WO2007058267A8 (ja) | 新規タンパク質及びそれをコードする遺伝子 | |
MX2010005816A (es) | Epítopos de péptido de stat3. | |
NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880112396.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08777198 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009528970 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 203898 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2696701 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/002001 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008290061 Country of ref document: AU Ref document number: 2008777198 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107005388 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1487/CHENP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010110564 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2008290061 Country of ref document: AU Date of ref document: 20080613 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12673434 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0815578 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100219 |